Immunotherapy targeting immune checkpoints such as PD-1/PD-L1 as well as CTLA- 4 restores the activity of depleted CD8 + T cells to kill tumor cells, resulting in good overall survival in mutation-negative patients [95, 96]. The gene discussed is CD8A; the disease is neoplasm.